🔎 Trials Near Me

Pradžia › Prostatos vėžys › Ohio

Prostatos vėžys klinikiniai tyrimai Ohio

65 tyrimai dėl Prostatos vėžys ieško dalyvių vietose Ohio.

Miestai Ohio

Oficialus tyrimo tekstas (anglų kalba)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • Aultman Health Foundation, Canton
  • Ohio State University Comprehensive Cancer Center, Columbus
  • ProMedica Flower Hospital, Sylvania
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-10-02 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  • MetroHealth Medical Center, Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-10-02 · NCT07200830

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • ir dar 44
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • MetroHealth Medical Center, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06632977

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
Renkami dalyviai2 fazė
Amžius 19 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06738303

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Strecker Cancer Center-Belpre, Belpre
  • Adena Regional Medical Center, Chillicothe
  • Ohio State University Comprehensive Cancer Center, Columbus
  • ir dar 22
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT03866382

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-28 · NCT06496256

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07124000

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07319871

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06136650

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-25 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
  • TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
  • University Hospitals Cleveland Medical Center, Cleveland
  • ir dar 2
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-24 · NCT07028853

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • Central Ohio Urology Group, Gahanna
Renkami dalyviai2/3 fazė
Amžius nuo 18 iki 100 · Vyrams · Atnaujinta 2026-09-22 · NCT06780670

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
  • The Ohio State University, Columbus
  • Dayton Physicians LLC Dayton, Dayton
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-22 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Urology Group - Solaris Network, Cincinnati
  • Central Ohio Urology Group, Gahanna
Renkami dalyviai3 fazė
Amžius nuo 18 iki 100 · Vyrams · Atnaujinta 2026-09-22 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  • Research Site, Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-18 · NCT06952803

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-17 · NCT06925737

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

  • University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-15 · NCT06150417

Investigation of Impact of AI on Prostate Cancer Workflow

  • Cleveland Clinic Foundation, Cleveland
Renkami dalyviai
Amžius nuo 55 iki 80 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07084779

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-15 · NCT07493512

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

  • University Hospitals Cleveland, Cleveland
Renkami dalyviai
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-14 · NCT06511141

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • ir dar 27
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-10 · NCT05946213

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  • Solaris Health - The Urology Group, Cincinnati
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-03 · NCT07005154

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  • Gabrail Cancer Center Research, Canton
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-03 · NCT07723248

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 45 iki 75 · Visoms lytims · Atnaujinta 2026-09-02 · NCT06995898

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Cleveland
  • Research Site, Dayton
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-26 · NCT07611110

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • Oncology Hematology Care Incorporated, Cincinnati
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-21 · NCT04221542

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  • The Ohio State University, Columbus
  • Taylor Cancer Research Center, Maumee
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-20 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-19 · NCT04423211

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • University Hospitals Cleveland Medical Center, Cleveland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-17 · NCT06842498

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
  • Cleveland Clinic, Cleveland
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05919264

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • University of Cincinnati Medical Center, Cincinnati
  • The Ohio State University, Columbus
Renkami dalyviai1 fazė
Amžius nuo 18 iki 100 · Vyrams · Atnaujinta 2026-08-13 · NCT05519449

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

  • Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Renkami dalyviai
Amžius 19 ir vyresni · Vyrams · Atnaujinta 2026-08-06 · NCT05610852

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

  • The Ohio State University, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-07-31 · NCT06613100

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • Cleveland Clinic Akron General, Akron
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • ir dar 15
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-07-14 · NCT06592924

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

  • Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-07-14 · NCT05691465

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  • The Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-07-09 · NCT07103018

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

  • Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-07-07 · NCT07406282

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.